Mark O'Connell

Title: Mark O'Connell: Innovator in Cancer Therapeutics

Introduction

Mark O'Connell is a notable inventor based in Montara, CA (US). He has made significant contributions to the field of cancer therapeutics, holding 2 patents that focus on the innovative use of Apo-2 ligand.

Latest Patents

His latest patents include methods for making Apo-2 ligand using divalent metal ions. These methods provide formulations that utilize divalent metal ions such as zinc and cobalt, which enhance Apo-2 ligand trimer formation and stability. Additionally, the patents detail the crystal structure of Apo-2 ligand and identify variant polypeptides through oligonucleotide-directed mutagenesis. Another significant patent describes a novel cytokine, designated Apo-2 ligand, which induces apoptosis in mammalian cancer cells. This cytokine is believed to belong to the TNF cytokine family and includes compositions such as Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand. Furthermore, methods for using Apo-2 ligand to induce apoptosis and treat pathological conditions like cancer are also provided.

Career Highlights

Mark O'Connell is currently associated with Genentech, Inc., where he continues to advance research in cancer treatment. His work has been pivotal in developing therapeutic strategies that leverage the properties of Apo-2 ligand.

Collaborations

Some of his notable coworkers include Avi J Ashkenazi and Robert F Kelley, who have collaborated with him on various projects related to cancer therapeutics.

Conclusion

Mark O'Connell's innovative work in the field of cancer therapeutics, particularly through his patents on Apo-2 ligand, showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his collaborations further enhance the impact of his research.